Inventor · disambiguated record
Ralf Lutterbüse
Also filed as: LUETTERBUSE RALF · LUTTERBUESE RALF · LUTTERBUSE RALF · LUTTERBÜSE Ralf
26 granted patents·17 pending applications·695 citations·filing 1998–2025
96Inventor score
Top patents by PatentIndex Score
43 records- 0197US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0296US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0396US7635472B2Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disordersMICROMET AG·Filed 2004·Granted Dec 22, 2009·158 cites·8 claims
- 0495US11472886B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Oct 18, 2022·3 cites·13 claims
- 0595US7575923B2CD19xCD3 specific polypeptides and uses thereofMICROMET AG·Filed 2006·Granted Aug 18, 2009·103 cites·4 claims
- 0694US9765157B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2015·Granted Sep 19, 2017·13 cites·14 claims
- 0794US7112324B1CD 19×CD3 specific polypeptides and uses thereofMICROMET AG·Filed 1999·Granted Sep 26, 2006·219 cites·23 claims
- 0893US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 0993US8101722B2Less immunogenic binding moleculesKUFER PETER·Filed 2005·Granted Jan 24, 2012·37 cites·23 claims
- 1092US9982063B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2016·Granted May 29, 2018·14 cites·25 claims
- 1188US11987633B2Cross-species-specific single domain bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted May 21, 2024·1 cites·27 claims
- 1287US11661462B2Optimized cross-species specific bispecific single chain antibody contructsAMGEN RES MUNICH GMBH·Filed 2015·Granted May 30, 2023·4 cites·12 claims
- 1387US10059766B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 28, 2018·9 cites·17 claims
- 1487US8394926B2Pharmaceutical compositions with resistance to soluble CEALUTTERBUESE RALF·Filed 2006·Granted Mar 12, 2013·21 cites·34 claims
- 1585US10981998B2Cross-species-specific single domain bispecific single chain antibodyKUFER PETER·Filed 2009·Granted Apr 20, 2021·5 cites·18 claims
- 1684US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 1783US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 1882US12297292B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2017·Granted May 13, 2025·2 cites·12 claims
- 1982US10851170B2Antibody constructs for CD70 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 1, 2020·3 cites·18 claims
- 2082US7435549B1Method of identifying binding site domains that retain the capacity of binding to an epitopeMICROMET AG·Filed 1998·Granted Oct 14, 2008·51 cites·47 claims
- 2180US9695250B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2013·Granted Jul 4, 2017·4 cites·19 claims
- 2279US11498964B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2018·Granted Nov 15, 2022·1 cites·17 claims
- 2378US12441796B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2022·Granted Oct 14, 2025·0 cites·17 claims
- 2478US2024166761A1Single chain binding molecules comprising N-terminal ABPAMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 2576US12304952B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 2676US2025092133A1Bispecific antibody constructs for cdh3 and cd3AMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 2775US12281172B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Apr 22, 2025·0 cites·18 claims
- 2872US2023057728A1Long life polypeptide binding moleculesAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 2970US11028171B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jun 8, 2021·1 cites·14 claims
- 3067US2011293619A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYKUFER PETER·Filed 2009·Application pending·0 cites
- 3166US11926666B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted Mar 12, 2024·0 cites·22 claims
- 3264US2020095319A1Cross-species-specific bispecific bindersAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 3364US2023357444A1Cross-species-specific binding domainAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 3462US2020071405A1Antibody constructs for cdh19 and cd3AMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 3561US2020362039A1Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalphaxcd3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 3661US2019169310A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYAMGEN RES MUNICH GMBH·Filed 2018·Application pending·0 cites
- 3759US2020040099A1Single chain binding molecules comprising N-terminal ABPAMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 3859US2012034228A1CROSS-SPECIES-SPECIFIC PSCAxCD3, CD19xCD3, C-METxCD3, ENDOSIALINxCD3, EPCAMxCD3, IGF-1RxCD3 OR FAPALPHAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYKUFER PETER·Filed 2009·Application pending·0 cites
- 3957US2021284748A1Antibody constructs for cd70 and cd3AMGEN RES MUNICH GMBH·Filed 2020·Application pending·0 cites
- 4056US2012244162A1Cross-species-specific bispecific bindersKUFER PETER·Filed 2012·Application pending·0 cites
- 4156US2019169295A1Long life polypeptide binding moleculesAMGEN RES MUNICH GMBH·Filed 2018·Application pending·0 cites
- 4253US2016152707A1Cross-species-specific bispecific bindersAMGEN RES MUNICH GMBH·Filed 2015·Application pending·0 cites
- 4336US2004038339A1Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complexFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ralf Lutterbüse files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →